Application of enilconazole in preparing drug for treating or preventing influenza virus infections

A technology for preventing influenza and virus infection, applied in the field of medicine, can solve problems such as no anti-influenza virus of enconazole, and achieve the effect of broad-spectrum antiviral activity and good safety

Inactive Publication Date: 2014-04-09
武汉威立得生物医药有限公司
View PDF1 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

But there is no report about enconazole anti-influenza virus

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of enilconazole in preparing drug for treating or preventing influenza virus infections
  • Application of enilconazole in preparing drug for treating or preventing influenza virus infections
  • Application of enilconazole in preparing drug for treating or preventing influenza virus infections

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0029] Embodiment 1: Evaluation of enconazole anti-influenza virus activity

[0030] 1. Experimental Materials

[0031] 1.1 Cells, viruses and drugs

[0032] MDCK cells were purchased from American Type Culture Collection (ATCC); virus strain: A / PuertoRico / 8 / 34 (H1N1); drug: enconazole was purchased from Sigma.

[0033] 1.2 Experimental Instruments

[0034] Multilabel microplate reader (Perkin Elmer).

[0035] 2. Experimental methods and results

[0036] 2.1 Cell culture: 37°C, 5% CO 2 cultured in a humidified incubator. A DMEM medium containing 10% FBS, 100 U / mL of penicillin and streptomycin was used. Cells were subcultured after reaching 90% confluence, and the subculture ratio was 1 / 3 – 1 / 4.

[0037] 2.2 Virus culture: Take SPF chicken embryos aged 9 to 11 days, check them with an egg tester before inoculating the virus, and mark them at a position far away from the embryos, disinfect and punch holes, and inoculate 2- 4 The virus liquid with hemagglutina...

Embodiment 2

[0047] Example 2: Evaluation of broad-spectrum anti-influenza virus effect of enconazole

[0048] In this experiment, enconazole was tested against influenza A subtype H1N1 strains, influenza A virus subtype H1N1 amantadine-resistant strains, influenza A virus subtype H7N8 strains, influenza A virus subtype H9N2 strains and influenza B Antiviral activity of viruses.

[0049] 1. The virus strains used in the experiment include: 1. The virus strains used in the experiment include: A / Human / Hubei / 1 / 2009(H1N1), A / human / WSN / 33 / (H1N1,S31N), A / Duck / Hubei / 216 / 1983(H7N8), A / Chicken / Jiangsu / 1 / 2005(H9N2), B / human / Hubei / 1 / 2007.

[0050] 2. Divide MDCK cells into 1.5×10 4 Cells / well were seeded in 96-well cell culture plates, cultured in a 37°C cell culture incubator for 14-18 hours, and the cells were grown into a single layer before use. Discard the medium in the well plate, wash twice with PBS, add 100TCID 50 Each well (100 μl) was infected with virus liquid, and at the same time...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses an application of enilconazole in preparing a drug for treating or preventing influenza virus infections. Firstly, toxicity of enilconazole to MDCK cells is detected. The result shows that the maximum non-toxic concentration of enilconazole is 100.0 [mu]M. Secondly, antiviral activity of enilconazole is measured within a completely non-toxic concentration range. The result shows that the small molecular compound has significant antiviral activity and the antiviral activity presents a dosage-dependent effect. Finally, the antiviral activities of enilconazole to influenza viruses in different types and subtypes are detected. The results show that enilconazole can suppress replication of all the detected influenza virus strains in a dose-dependent manner, so that the anti-influenza virus activity of enilconazole has a broad spectrum. Therefore, enilconazole disclosed by the invention is a novel broad-spectrum anti-influenza virus drug and can be used for preparing the drug for treating or preventing the influenza virus infections.

Description

technical field [0001] The invention relates to the application of enconazole in the preparation of medicines for treating or preventing influenza virus infection, belonging to the technical field of medicine. Background technique [0002] Influenza viruses belong to the family Orthomyxoviridae, the genus Influenzavirus. According to the differences in the antigenic and genetic characteristics of the virion nucleoprotein (NP) and matrix protein (M), influenza viruses are divided into three types: A, B, and C, also known as A, B, and C. The whole genome of influenza A virus consists of eight single-stranded negative-strand RNAs of different sizes, named after segment 1 to segment 8, respectively. The full-length viral genome is about 13.6 kb, encoding 10 structural proteins (PB2, PB1, PA, HA, NP, NA, M1, M2, PB1-F2 and NS2 / NEP) and non-structural proteins (NS1). Influenza A viruses can be further divided into 17 H (H1-H17) and 10 N (N1-N10) subtypes according to the differe...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/4174A61P31/16
Inventor 陈绪林安利伟
Owner 武汉威立得生物医药有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap